United Therapeutics Corporation

United Therapeutics develops and commercializes products for chronic and life-threatening diseases. Products include Tyvaso DPI, Tyvaso, Remodulin, Orenitram, Adcirca, Unituxin, and Remunity Pump. The company also develops RemoPro, Ralinepag, Aurora-GT, and Nebulized Tyvaso. Licensing agreements include DEKA Research, MannKind Corporation, and Arena Pharmaceuticals. The company was incorporated in 1996 and is headquartered in Maryland.

Overview

Sector

Pharmaceutical

Target Price

505.9 USD

Current Price

455.3 USD

Potential

11%

Strengths

Current Price to Earnings Ratio (17.08) is lower than the sector mean (289.29).
The company has low debt. Net Debt to EBITDA Ratio is -0.81 and it is lower than the sector mean.
The company has high returns. ROIC (19.68%) is higher than the sector mean (14.71%).
EV/EBIT (12.02) is lower than the sector mean.
Price to free cash flow (18.89) is lower than the sector mean.
Strong EBITDA Margin of 59.97%.

Weaknesses

No significant weaknesses identified based on the analyzed metrics.

Indicator	Value
PER	17.1
EV/EBITDA	11.0
Price/Free Cash Flow'	18.9
ROIC	19.7%
Net Debt/EBITDA	-0.8

United Therapeutics Corporation

Overview

Strengths

Weaknesses

Key Financial Data